Stifel Nicolaus Cuts Insmed (NASDAQ:INSM) Price Target to $96.00

Insmed (NASDAQ:INSM) had its price target decreased by Stifel Nicolaus from $97.00 to $96.00 in a research report released on Friday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on INSM. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday. Finally, Guggenheim boosted their price objective on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.00.

Insmed Price Performance

Shares of NASDAQ INSM opened at $81.06 on Friday. The firm has a market cap of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91. The business’s 50 day moving average is $74.29 and its 200-day moving average is $73.61.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities research analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. This represents a 4.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now owns 102,766 shares in the company, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp raised its stake in Insmed by 12.5% during the 4th quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 1,213 shares during the period. GF Fund Management CO. LTD. acquired a new position in Insmed during the 4th quarter worth approximately $259,000. Fourth Dimension Wealth LLC acquired a new position in Insmed during the 4th quarter worth approximately $278,000. Vise Technologies Inc. raised its stake in Insmed by 6.3% during the 4th quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock worth $389,000 after buying an additional 336 shares during the period. Finally, Castleark Management LLC raised its stake in shares of Insmed by 21.9% in the fourth quarter. Castleark Management LLC now owns 52,780 shares of the biopharmaceutical company’s stock worth $3,644,000 after purchasing an additional 9,480 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.